In earlier proof-of-concept work, a single oral dose of TP-05 (lotilaner) produced more than 90% tick mortality within 24 hours of attachment at the Day 1 challenge versus 5% with placebo (p<0.001) and maintained a statistically significant kill effect at Day 30. Preclinical pilot studies reported 90% prevention of Lyme infection in mice versus 0% in controls, and TP-05 was generally well tolerated in the Phase 2a setting. Tarsus has now dosed the first participant in Calliope, a randomized, double-blind, placebo-controlled Phase 2 study enrolling approximately 700 healthy adults at risk for Lyme disease across endemic U.S. regions. The trial is designed to evaluate safety, tolerability, and pharmacokinetics of an on‑demand oral prophylactic intended to kill ticks before Borrelia transmission. Enrollment is slated to complete during the 2026 tick season, with topline data expected in the first half of 2027. There are currently no FDA‑approved pharmacologic prophylactic options for Lyme, positioning TP‑05 as a novel, non‑vaccine approach if efficacy can be substantiated. Strategically, Tarsus is pursuing a prevention model that sits between vaccine-based season‑long protection and post‑exposure antibiotic use. The company is leaning on a well‑characterized isoxazoline mechanism that has extensive veterinary precedent for systemic ectoparasite control, while attempting to translate a clear pharmacodynamic signal—rapid tick kill—into a regulatory path in humans. The choice to prioritize safety, tolerability, and PK in a large Phase 2 suggests this study is primarily about dose/regimen definition, exposure coverage across the tick season, and de‑risking class‑related safety before committing to incidence‑based efficacy in Phase 3. The central tension is whether a tick‑kill surrogate, even with strong PK/PD correlation, will be sufficient to streamline development, or whether regulators will insist on field efficacy against laboratory‑confirmed Lyme infections, which would drive up sample size, timelines, and operational complexity. For sites, this program is operationally seasonal and geographically concentrated. Investigators will need rapid screening and activation aligned to local tick activity, infrastructure to capture exposures in real time, and standardized case ascertainment using serology and PCR to adjudicate incident infections. Expect heavy reliance on ePRO for bite reporting, telephonic triage, and potentially mail‑in tick submission, coupled with centralized labs and tight follow‑up windows to map PK to exposure risk. CROs will be balancing wide regional dispersion with the need for consistent bite/illness surveillance and may deploy decentralized elements to stabilize retention across a transient, outdoor‑active population. Public health stakeholders will watch endpoint selection closely; case definitions and surveillance alignment with CDC practices will influence both regulatory reception and eventual guideline adoption. For sponsors with vaccine assets or those leveraging post‑exposure doxycycline, the emergence of an on‑demand oral tick‑kill option could reshape prevention algorithms, particularly for occupational groups, travelers, and communities facing expanding tick ranges. The next inflection hinges on two readouts: durability of systemic tick‑kill at later time points and a clean neurologic safety profile typical of human isoxazoline exposure. Those data will dictate Phase 3 architecture—season‑long versus episodic dosing, event‑driven incidence endpoints, and required sample size to capture enough confirmed Lyme cases. Watch for whether FDA entertains a PD‑anchored expedited path or signals a firm requirement for infection reduction across a season, as well as how this program times against vaccine developments and evolving CDC guidance on antibiotic prophylaxis. Manufacturing scale and distribution that can flex to seasonal demand spikes will also matter if TP‑05 advances, but the immediate question for the sector is whether a clear PD mechanism can meaningfully compress the prevention trial paradigm in a disease with variable, geographically shifting exposure risk.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
